



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

Date: May 30, 2024

To,
Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Subject: Submission of Newspaper Advertisement under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith copies of Newspaper advertisement dated May 30, 2024 for the fourth quarter and financial year ended March, 31 2024 Financial Results published in English Newspaper 'Business Standard' and Marathi Newspaper 'Mumbai Lakshdeep' respectively.

The said publication may also be accessed on the website of the company i.e <https://www.aspiradiagnostics.com/> as per regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Kindly take the same on your record.

Thanking you.

Yours Faithfully,
For **Aspira Pathlab & Diagnostics Limited**

Krupali Shah
Company Secretary & Compliance Officer

Encl: As above

INDIA'S FIRST
FULLY INTEGRATED LAB

☎ 0227197 5756, 022 2513 9090 🌐 www.aspiradiagnostics.com
✉ support@aspiradiagnostics.com | info@aspiradiagnostics.com

CK BIRLA GROUP ORIENT PAPER		ORIENT PAPER & INDUSTRIES LIMITED				
[Regd. Office : Unit VIII, Plot 7, Bhoingar, Bhubaneswar - 751012 (Odisha)]						
Tel: (0674) 2396930 E-mail: paper@opilbbsr.com						
CIN: L21011OR1936PLC000117						
Extract of Audited Financial Results for the year ended 31st March, 2024						
(₹ In lacs)						
Sl. No.	Particulars	Quarter Ended			Year Ended	
		31-03-2024 (Audited)	31-12-2023 (Unaudited)	31-03-2023 (Audited)	31-03-2024 (Audited)	31-03-2023 (Audited)
1	Total income from operations	24,236.57	20,336.76	25,847.57	83,194.35	94,295.67
2	Profit / (Loss) Before Tax	(1,393.62)	109.46	7,174.23	1,376.01	14,765.73
3	Net Profit / (Loss) for the period	(641.89)	(321.91)	4,995.25	622.53	9,924.57
4	Other comprehensive income not to be reclassified to Profit & Loss in subsequent periods (net of tax)	299.28	2,911.73	(1,396.30)	11,821.17	(13,131.77)
5	Total comprehensive income / loss (3+4)	(342.61)	2,589.82	3,598.95	12,443.70	(3,207.20)
6	Paid-up equity share capital (Face value per share : Re.1/-)	2,121.96	2,121.96	2,121.96	2,121.96	2,121.96
7	Other Equity				1,59,776.34	1,49,425.96
8	Earning per Equity Share of face value of Re.1/- each (Not Annualised) Basic & Diluted	(0.31)	(0.15)	2.35	0.29	4.68

Notes:

- The Board has recommended a dividend of Rs.0.25 (25%) per equity share of face value of Re. 1/- each for the year ended 31st March 2024 subject to the approval of the shareholders at the ensuing Annual general meeting.
- The above financial results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on May 29, 2024. The financial results for the year ended 31 March 2024 have been subjected to audit by the Company's Statutory Auditors, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have issued an unmodified report thereon.
- The above is an extract of the detailed format of Audited Financial Results for the year ended 31st March, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites. (www.bseindia.com / www.nseindia.com) and Company's website (www.orientpaperindia.com).

By Order of the Board
for ORIENT PAPER & INDUSTRIES LIMITED
Sd/-
(Ashwin J. Laddha)
Managing Director & CEO
(DIN 09538310)

Kolkata
May 29, 2024

SUPRAJIT ENGINEERING LIMITED		Statement of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended March 31, 2024. (Rs. in Million)									
Regd Office: No 100 & 101, Bommasandra Industrial Area, Anekal Taluk, Bengaluru-560 099. Website - www.suprajit.com, email - info@suprajit.com CIN - L29199KA1985PLC006934		STANDALONE					CONSOLIDATED				
Particulars	For the Quarter ended		Year ended			For the Quarter ended		Year ended			
	31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023	31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023	
	Audited	Unaudited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited	
1	Total Income from operations	4,128.12	4,052.14	3,394.86	15,367.36	14,310.19	7,831.22	7,241.76	6,990.09	28,958.55	27,523.55
2	Net profit / (Loss) for the period (before tax, exceptional and / or extraordinary items #)	764.48	749.96	500.70	2,903.00	2,476.79	734.45	571.81	580.91	2,277.75	2,202.40
3	Net profit / (Loss) for the period before tax (after exceptional and / or extraordinary items #)	764.48	749.96	500.70	2,903.00	2,476.79	734.45	571.81	580.91	2,277.75	2,202.40
4	Net profit / (Loss) for the period after tax (after tax, exceptional and / or extraordinary items #)	690.31	573.22	385.55	2,359.93	1,867.82	591.50	402.46	410.09	1,672.70	1,521.09
5	Total comprehensive income for the period [Comprising profit / Loss for the period (after tax) and other comprehensive income (after tax)]	697.58	573.49	393.93	2,350.55	1,865.67	580.26	468.52	530.42	1,690.91	1,678.25
6	Equity share capital (face value of Re.1/- each per share)	138.46	138.43	138.39	138.46	138.39	138.46	138.43	138.39	138.46	138.39
7	Earning per share (of Re.1 each) (for continuing and discontinued operations) Basic	4.99	4.14	2.79	17.05	13.50	4.27	2.91	2.96	12.08	10.99
8	Earning per share (of Re.1 each) (for continuing and discontinued operations) Diluted	4.98	4.13	2.78	17.02	13.48	4.26	2.90	2.96	12.06	10.98

Note:

The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the stock exchange web sites, at a link (<http://www.bseindia.com/corporates>) and (<https://nseindia.com/corporates>) and on the company's website at www.suprajit.com.

Particulars	Standalone-YTD			Consolidated-YTD		
	31.03.2024	31.03.2023	Growth	31.03.2024	31.03.2023	Growth
Net Revenue from operations	15,367.36	14,310.19	7.39	28,958.55	27,523.55	5.21

For and on behalf of the Board of Directors
K. AJITH KUMAR RAI
Chairman
(DIN - 01160327)

Place : Bengaluru
Date : May 29, 2024

ASPIRA PATHLAB & DIAGNOSTICS LIMITED		CIN:- L85100MH1973PLC289209				
Reg. Office : Flat No.2, R.D.Shah Building, Shradhdhanand Road, Opp. Railway Station, Ghatkopar (W.), Mumbai -400086 Tel No.: 71975656 ;						
email ID: info@aspiradiagnostics.com ; website: www.aspiradiagnostics.com						
Extract of Audited Financial Results for the year ended March 31, 2024						
(Rupees in Lakhs)						
Sr No	Particulars	Quarter Ended			Year Ended	
		31.03.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2023 (Unaudited)	31.03.2024 (Audited)	31.03.2023 (Audited)
1.	Total income from operations	381.79	346.17	340.76	1320.49	1445.69
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(50.26)	(74.19)	(25.93)	(267.22)	(8.87)
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(50.26)	(74.19)	(25.93)	(267.22)	(8.87)
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(50.26)	(74.19)	(25.93)	(267.22)	(8.87)
5.	Total Comprehensive Income for the period (Comprising profit/(loss) for the period(after tax) and other Comprehensive Income(after tax)	6.51	-	4.96	6.51	4.96
6.	Equity Share Capital	1029.30	1029.30	1029.30	1029.30	1029.30
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	-	-	-	-	-
8.	Earnings Per Share (of ₹10/- each) (for continuing and discontinued operations)- Basic: Diluted:	(0.49) (0.49)	(0.72) (0.72)	(0.25) (0.25)	(2.60) (2.60)	(0.09) (0.09)

Note:

- The above is an extract of the detailed format of Audited Financial Results for the Year ended March 31, 2024, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the year ended March 31, 2024 is available on the websites of the Stock Exchange(s) and the company's website:- www.aspiradiagnostics.com.
- The above result has been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on May 28, 2024.

For and on behalf of the Board
For Aspira Pathlab & Diagnostics Limited
Sd/-
Nikunj V. Mange
Executive Director
DIN. 08489442

Place:- Mumbai
Date:- May 28, 2024

GENUS POWER INFRASTRUCTURES LIMITED		CIN: L51909UP1992PLC051997									
Regd. Office : G-123, Sector-63, Noida-201307, Uttar Pradesh (Tel: +91-120-2581999) Corporate Office: SPL-3, RIICO Industrial Area, Sitapura, Tonk Road, Jaipur-302022, Rajasthan Ph.:0141-7102400/500, Fax: 0141-2770319, E-mail: cs@genus.in, Website: www.genuspowers.com, CIN: L51909UP1992PLC051997		STANDALONE					CONSOLIDATED				
S. No	Particulars	Quarter Ended on		Year Ended on			Quarter Ended on		Year Ended on		
		31 March, 24	31 Dec, 23	31 March, 23	31 March, 24	31 March, 23	31 March, 24	31 Dec, 23	31 March, 23	31 March, 24	31 March, 23
		Audited	Unaudited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited
1	Total income from operations	42,011.75	25,978.03	20,232.17	120,058.25	80,838.55	42,011.75	25,978.03	20,232.17	120,058.25	80,838.55
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	4,758.61	2,165.43	1,754.87	11,191.93	5,027.37	4,553.65	620.20	(948.05)	13,966.03	4,480.92
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	4,758.61	2,165.43	1,754.87	11,191.93	5,027.37	4,553.65	620.20	(948.05)	13,966.03	4,480.92
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	3,137.33	1,352.32	1,247.29	7,517.18	3,498.42	2,434.74	(992.44)	(1,128.58)	8,666.50	2,897.43
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	3,115.00	1,352.99	1,216.74	7,641.12	3,435.05	2,412.41	(991.77)	(1,159.13)	8,790.44	2,834.06
6	Paid-up Equity Share Capital (Face Value of Re.1/- each)	3,037.55	2,577.76	2,575.95	3,037.55	2,575.95	3,037.55	2,577.76	2,575.95	3,037.55	2,575.95
7	Other equity (Reserves)	-	-	-	153,357.83	95,879.23	-	-	-	154,327.71	95,719.39
8	Earnings Per Share (Face value of Re.1/- each) (for continuing and discontinued operations) - (not annualised) (Amount in Rs.) Basic : Diluted:	1.06 1.05	0.52 0.51	0.49 0.48	2.81 2.79	1.36 1.35	0.90 0.90	(0.43) (0.43)	(0.49) (0.48)	3.61 3.59	1.26 1.25

Notes:

1 The above is an extract of the detailed format of financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, as amended. The full format of the financial results are available on Company's website at www.genuspowers.com and the Stock Exchanges website (www.nseindia.com and www.bseindia.com).

For and on behalf of the Board of Directors
Sd/-
(Rajendra Kumar Agarwal)
Managing Director & CEO
DIN: 00011127

Place: Jaipur
Date : May 29, 2024

Balaxi Pharmaceuticals Limited

Registered Office: 2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598
Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2024

(Rs. in Lakhs, unless specified)

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter ended		Year ended		Quarter ended		Year ended	
		31/03/2024	31/03/2024	31/03/2023	31/03/2023	31/03/2024	31/03/2024	31/03/2023	31/03/2023
1	Total Income from Operations	1,590.45	7,019.60	3,035.14	10,813.76	5,983.31	24,129.44	8,068.15	33,643.26
2	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	(26.42)	558.31	508.73	2,245.05	1,040.43	4,030.88	1,106.83	5,692.23
3	Net profit/(loss) for the period before tax (after exceptional and/or extraordinary items)	(26.42)	558.31	508.73	2,245.05	1,149.36	201.54	1,106.83	5,692.23
4	Net profit/(loss) for the period after tax (after exceptional and/or extraordinary items)	(57.52)	365.03	394.31	1,622.21	1,093.38	(238.69)	810.03	4,596.25
5	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	(57.52)	365.03	394.31	1,622.21	1,061.34	(730.58)	791.55	5,174.44
6	Paid-up Equity Share Capital (Face value of Rs. 10 each)	1,089.77	1,089.77	1,018.13	1,018.13	1,089.77	1,089.77	1,018.13	1,018.13
7	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year		11,064.91		8,192.53		19,046.56		17,269.85
8	Earnings Per Share (of Rs.10/- each) 1. Basic (amount in Rs.) 2. Diluted (amount in Rs.)	(0.55) (0.55)	3.55 3.54	3.90 3.83	16.17 16.02	10.41 10.38	(2.32) (2.31)	8.01 7.86	45.81 45.40

Notes:

- The above is an extract of the detailed format of Financial Results for the quarter and year ended March 31, 2024 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Audited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.
- The above Audited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 29, 2024 respectively. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of Board of Directors,
Balaxi Pharmaceuticals Limited
Ashish Maheshwari
Managing Director
DIN: 01575984

Place: Hyderabad
Date: May 29, 2024

RENAISSANCE GLOBAL LIMITED

CIN L36911MH1989PLC054498
Regd Office : Plot Nos. 36A & 37, SEEPZ-SEZ, Andheri (East), Mumbai - 400 096.

AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED MARCH 31, 2024

(₹ in Lakhs)

Sr No.	Particulars	Quarter Ended			Year Ended	
		Mar 31, 2024 Audited	Dec 31, 2023 Unaudited	Mar 31, 2023 Audited	Mar 31, 2024 Audited	Mar 31, 2023 Audited
1	Total Income from Operations (net)	53,958.79	65,787.80	50,137.74	2,11,695.27	2,24,268.04
2	Net Profit before tax and Exceptional items	2,309.60	3,234.60	1,849.86	8,540.47	9,477.34
3	Net Profit after tax and Exceptional items	2,103.79	2,788.16	1,973.48	7,360.19	8,780.83
4	Total Comprehensive Income for the period / year [Comprising Profit/(Loss) for their period/year (after tax) and other Comprehensive Income (after tax)]	3,199.01	3,978.87	4,102.70	12,202.22	10,346.36
5	Equity Share Capital (Face Value of ₹ 2/- each)	1,922.63	1,922.63	1,887.94	1,922.63	1,887.94
6	Earning Per Share EPS (of ₹ 2/- each not annualised) Continuing Operations Basic Diluted	2.05 2.03	2.92 2.91	2.16 2.14	7.59 7.54	9.28 9.22
	Discontinued Operations Basic Diluted	- -	- -	-0.01 -0.01	- -	0.06 0.06
	Continuing and Discontinued Operations Basic Diluted	2.05 2.04	2.92 2.91	2.15 2.13	7.59 7.54	9.22 9.16

NOTES:

- The above Audited Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 29, 2024.
- The above is an extract of the detailed format of quarterly / yearly financial results filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financials results are available on the websites of Stock Exchanges www.bseindia.com and www.nseindia.com and also on the Company's website www.renaissanceglobal.com.
- Key numbers of Standalone Results are as under:

Particulars	Quarter Ended			Year Ended	
	Mar 31, 2024 Audited	Dec 31, 2023 Unaudited	Mar 31, 2023 Audited	Mar 31, 2024 Audited	Mar 31, 2023 Audited
Revenue	34,828.31	42,935.11	30,694.15	1,39,607.73	1,35,735.35
Profit Before Tax	404.16	790.73	(219.48)	2,738.58	2,745.37
Profit After Tax	342.95	567.37	(248.66)	2,071.39	2,006.46
Total Comprehensive income for the period/year after tax	419.52	684.47	870.94	3,170.96	955.02

For RENAISSANCE GLOBAL LIMITED

Place : Mumbai
Dated : May 29, 2024

HITESH M. SHAH
MANAGING DIRECTOR
DIN No. 00036338

